ASP8825 - Study in Patients With Restless Legs Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with RLS, based on the International RSL Study Group Diagnostic Criteria
History of RLS symptoms at least 15 nights in the prior month or, if on treatment, this frequency of symptoms before treatment was started
Documented RLS symptoms for at least 4 of the 7 consecutive evenings/ nights during the baseline study period
A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of RLS
A history of RLS symptom augmentation or end-of-dose rebound with previous dopamine agonist treatment
Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's Disease, Multiple Sclerosis, dyskinesias and dystonias